[go: up one dir, main page]

WO2004082581A3 - Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives - Google Patents

Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives Download PDF

Info

Publication number
WO2004082581A3
WO2004082581A3 PCT/FR2004/000532 FR2004000532W WO2004082581A3 WO 2004082581 A3 WO2004082581 A3 WO 2004082581A3 FR 2004000532 W FR2004000532 W FR 2004000532W WO 2004082581 A3 WO2004082581 A3 WO 2004082581A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
pharmaceutical compositions
carbon
cholest
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2004/000532
Other languages
English (en)
Other versions
WO2004082581A2 (fr
Inventor
Thierry Bordet
Cyrille Drouot
Bruno Buisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trophos SA
Original Assignee
Trophos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0302992A external-priority patent/FR2852246B1/fr
Priority claimed from FR0311324A external-priority patent/FR2860159B1/fr
Priority to JP2006505701A priority Critical patent/JP4970932B2/ja
Priority to DK04717660.7T priority patent/DK1601363T3/da
Priority to BRPI0408240-0A priority patent/BRPI0408240A/pt
Priority to AU2004222540A priority patent/AU2004222540B2/en
Priority to ES04717660T priority patent/ES2388669T3/es
Priority to PL04717660T priority patent/PL1601363T3/pl
Priority to EP04717660A priority patent/EP1601363B1/fr
Priority to US10/548,473 priority patent/US7858603B2/en
Priority to CA2517893A priority patent/CA2517893C/fr
Application filed by Trophos SA filed Critical Trophos SA
Publication of WO2004082581A2 publication Critical patent/WO2004082581A2/fr
Publication of WO2004082581A3 publication Critical patent/WO2004082581A3/fr
Priority to IL170348A priority patent/IL170348A/en
Anticipated expiration legal-status Critical
Priority to US12/776,217 priority patent/US8283341B2/en
Priority to US13/591,789 priority patent/US8354395B2/en
Priority to US13/591,774 priority patent/US8575138B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Composé de formule (I) où X = O ou groupement = N-OH, R représente un groupement choisi parmi A = hydrogène ou ensemble avec B une liaison carbone-carbone, B = hydrogène, hydroxy ou ensemble avec A une liaison carbone-carbone, C, D, E, F = hydrogène ou ensemble avec D une liaison carbone-carbone, ou l’un de ses sels d'addition avec les acides pharmaceutiquement acceptables, à l'exception de quelques composés, à titre de médicament, application notamment comme neuroprotecteurs, nouveaux composés de formule (I) et compositions pharmaceutiques.
PCT/FR2004/000532 2003-03-11 2004-03-05 Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives Ceased WO2004082581A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2517893A CA2517893C (fr) 2003-03-11 2004-03-05 Application a titre de medicaments de derives de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
US10/548,473 US7858603B2 (en) 2003-03-11 2004-03-05 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof
DK04717660.7T DK1601363T3 (da) 2003-03-11 2004-03-05 Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
BRPI0408240-0A BRPI0408240A (pt) 2003-03-11 2004-03-05 composto, utilização de um composto e composição farmacêutica
AU2004222540A AU2004222540B2 (en) 2003-03-11 2004-03-05 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof
JP2006505701A JP4970932B2 (ja) 2003-03-11 2004-03-05 コレスト−４−エン−３−オンの誘導体の医薬としての使用、これらを含む医薬組成物、新規誘導体及びそれらの製造方法
ES04717660T ES2388669T3 (es) 2003-03-11 2004-03-05 Aplicación como medicamentos de los dreivados de colest-4-en-3-ona, composiciones farmacéuticas que los contienen y nuevos derivados
PL04717660T PL1601363T3 (pl) 2003-03-11 2004-03-05 Zastosowanie pochodnych cholest-4-en-onu jako leków, kompozycje farmaceutyczne zawierające te pochodne, nowe pochodne i sposób ich wytwarzania
EP04717660A EP1601363B1 (fr) 2003-03-11 2004-03-05 Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
IL170348A IL170348A (en) 2003-03-11 2005-08-18 Annals of Colest-4-and-3-On Oxes, Containing and Using Pharmaceutical Preparations
US12/776,217 US8283341B2 (en) 2003-03-11 2010-05-07 Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process
US13/591,774 US8575138B2 (en) 2003-03-11 2012-08-22 Method for providing neuroprotection
US13/591,789 US8354395B2 (en) 2003-03-11 2012-08-22 Method for providing neuroprotection from spinal muscular atrophy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0302992A FR2852246B1 (fr) 2003-03-11 2003-03-11 Utilisation de l'oxime de cholest-4-en-3-one dans le traitement des affections du motoneurone
FR03/02992 2003-03-11
FR0311324A FR2860159B1 (fr) 2003-09-26 2003-09-26 Utilisation de l'oxime de cholest-4-en-3-one en tant que medicament neuroprotecteur
FR03/11324 2003-09-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10548473 A-371-Of-International 2004-03-05
US12/776,217 Division US8283341B2 (en) 2003-03-11 2010-05-07 Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process

Publications (2)

Publication Number Publication Date
WO2004082581A2 WO2004082581A2 (fr) 2004-09-30
WO2004082581A3 true WO2004082581A3 (fr) 2004-10-28

Family

ID=33031360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000532 Ceased WO2004082581A2 (fr) 2003-03-11 2004-03-05 Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives

Country Status (12)

Country Link
US (4) US7858603B2 (fr)
EP (1) EP1601363B1 (fr)
JP (1) JP4970932B2 (fr)
AU (1) AU2004222540B2 (fr)
BR (1) BRPI0408240A (fr)
CA (1) CA2517893C (fr)
DK (1) DK1601363T3 (fr)
ES (1) ES2388669T3 (fr)
IL (1) IL170348A (fr)
PL (1) PL1601363T3 (fr)
PT (1) PT1601363E (fr)
WO (1) WO2004082581A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874923B1 (fr) * 2004-09-07 2006-10-27 Trophos Sa Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
FR2894968B1 (fr) * 2005-12-20 2008-02-22 Trophos Sa Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
FR2899108B1 (fr) * 2006-03-31 2012-02-03 Trophos Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur
FR2907783A1 (fr) * 2006-10-30 2008-05-02 Trophos Sa Nouveaux composes chimiques, leurs procedes de synthese et leur utilisation a titre de medicament, particulierement a titre de medicament cytoprotecteur, neuroprotecteur ou cardioprotecteur
FR2914188B1 (fr) * 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
US20080275259A1 (en) * 2007-05-04 2008-11-06 Scinopharm Taiwan, Ltd Process for preparing aromatase inhibitors
AR061892A1 (es) * 2007-07-11 2008-10-01 Consejo Nac Invest Cient Tec Un compuesto que presenta actividad antiinflamatoria y actividad antiviral, composiciones farmaceuticas que lo comprenden, un procedimiento para su obtencion y uso del mismo en el tratamiento de la queratoconjuntivitis epidemica y de la queratitis estromal herpetica
FR2919180B1 (fr) * 2007-07-25 2009-11-27 Trophos Utilisation d'au moins un derive oxime de la cholest-4-en-3-one comme antioxydants
AU2008348717B2 (en) * 2007-10-30 2013-09-19 Trophos Novel composition for treating the side effects of anticancer treatments
EP2260052A4 (fr) * 2008-02-26 2013-01-16 Univ Emory Analogues stéroïdiens utilisés en neuroprotection
FR2934596B1 (fr) * 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用
US9447139B2 (en) 2010-04-09 2016-09-20 The Research Foundation Of State University Of New York Ship inhibitors and uses thereof
WO2012069150A2 (fr) 2010-11-22 2012-05-31 Powerpore Gmbh Cytoprotecteurs pour la prévention d'effets secondaires médicamenteux
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
ES2886839T3 (es) * 2013-08-12 2021-12-21 Univ Emory Análogos de fosfato de progesterona y usos relacionados con los mismos
US10758548B2 (en) * 2015-05-20 2020-09-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treating peripheral demyelinating diseases
CN108289959B (zh) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物
CN109152788A (zh) * 2016-06-03 2019-01-04 豪夫迈·罗氏有限公司 Sma的新型治疗
WO2018073141A1 (fr) 2016-10-18 2018-04-26 F. Hoffmann-La Roche Ag Nouvelle composition pour le traitement de la sma
CN108938648A (zh) * 2018-06-21 2018-12-07 中山大学 胆甾-3,6-二酮用于神经元损伤的治疗
KR102812083B1 (ko) * 2021-12-01 2025-05-27 동국대학교 와이즈캠퍼스 산학협력단 3β, 6β-디-아세톡시-5-히드록시-5α-콜레스탄을 포함하는 신경세포 발달 촉진용 조성물 및 이를 이용한 신경세포 성장 촉진 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442350A1 (fr) * 1990-02-16 1991-08-21 Boots Pharma GmbH Préparation médicale contenant le stigmasta-4-ène-3-one et son utilisation
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52116456A (en) * 1976-03-25 1977-09-29 Takasago Corp Preparation of 3-keto- #4-steroid
US5264428A (en) * 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH0748397A (ja) * 1993-08-05 1995-02-21 Taisho Pharmaceut Co Ltd ステロイド化合物
ES2106616T3 (es) * 1994-05-19 1997-11-01 Akzo Nobel Nv Derivados de 11,21-bisfenilo-19-nor-pregnanos.
JP2001031572A (ja) * 1999-07-22 2001-02-06 Kyorin Pharmaceut Co Ltd ジクチオステロールを有効成分とする中枢神経細胞突起再生薬
DE19961219A1 (de) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442350A1 (fr) * 1990-02-16 1991-08-21 Boots Pharma GmbH Préparation médicale contenant le stigmasta-4-ène-3-one et son utilisation
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AHMAD, M.S.; SIDDIQUI, A.H. ET AL: "Azasteroid from cholest-4,6-dien-3-one", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 22, no. 1, 1969, pages 271 - 274, XP008033857 *
DATABASE CAPLUS CHEMICAL ABSTRACT SERVICE, COLUMBUS; 29 January 2002 (2002-01-29), KAWAHARA, TOMIO ET AL: "Preparation of ergostenols and neuron projection regenerants", XP002292135 *
HORITA, KIYOSHI ET AL: "Anti-arrhythmia constituent in Herba leonuri", NATURAL MEDICINES (TOKYO, JAPAN) , 56(5), 212-214 CODEN: NMEDEO; ISSN: 1340-3443, 2002, XP008033780 *
KANEKO, EMI ET AL: "Induction of Intestinal ATP-binding Cassette Transporters by a Phytosterol-derived Liver X Receptor Agonist", JOURNAL OF BIOLOGICAL CHEMISTRY , 278(38), 36091-36098 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP001199518 *
KOBAYASHI M ET AL: "POLYPHOSPHORIC ACID-CATALYZED BECKMANN REARRANGEMENT OF 3-KETO-STEROID OXIMES", CHEMICAL AND PHARMACEUTICAL BULLETIN, TOKYO, JP, vol. 17, no. 6, 1969, pages 1255 - 1260, XP008029833, ISSN: 0009-2363 *
KOLAK, UFUK ET AL: "Cardioactive diterpenoids from the roots of Salvia amplexicaulis", PLANTA MEDICA , 67(8), 761-763 CODEN: PLMEAA; ISSN: 0032-0943, 2001, XP008033781 *
LIN, WEI-YU ET AL: "Anti-platelet aggregation and chemical constituents from the rhizome of Gynura japonica", PLANTA MEDICA , 69(8), 757-764 CODEN: PLMEAA; ISSN: 0032-0943, 2003, XP008033801 *
SUZUKI K ET AL: "The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 16, 18 August 1998 (1998-08-18), pages 2133 - 2138, XP004137233, ISSN: 0960-894X *
UENSEREN E: "GAMMA IRRADIATION OF CHOLESTENONE OXIMES", INIS ATOMINDEX, INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, AT, vol. 8, no. 6, 1977, pages 1 - 21,4PAGES, XP001164118, ISSN: 0004-7139 *
YANG, Y. ET AL: "Anti-emetic principles of Pogostemon cablin", PHYTOMEDICINE , 6(2), 89-93 CODEN: PYTOEY; ISSN: 0944-7113, 1999, XP008033811 *

Also Published As

Publication number Publication date
AU2004222540B2 (en) 2009-10-01
PL1601363T3 (pl) 2012-11-30
JP4970932B2 (ja) 2012-07-11
CA2517893A1 (fr) 2004-09-30
US20100216752A1 (en) 2010-08-26
US8283341B2 (en) 2012-10-09
EP1601363B1 (fr) 2012-06-20
US8575138B2 (en) 2013-11-05
IL170348A (en) 2014-02-27
EP1601363A2 (fr) 2005-12-07
ES2388669T3 (es) 2012-10-17
US7858603B2 (en) 2010-12-28
US8354395B2 (en) 2013-01-15
US20060217358A1 (en) 2006-09-28
BRPI0408240A (pt) 2006-03-01
CA2517893C (fr) 2012-05-15
AU2004222540A1 (en) 2004-09-30
US20120309721A1 (en) 2012-12-06
PT1601363E (pt) 2012-08-17
US20120316141A1 (en) 2012-12-13
JP2006519819A (ja) 2006-08-31
DK1601363T3 (da) 2012-09-03
WO2004082581A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
EP1400529A4 (fr) Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci
CA2408142A1 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2007061360A3 (fr) Nouveau composes
GB0206860D0 (en) Compounds
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EP1340755A4 (fr) Agents de traitement des infections a helicobacter
HK1043594A1 (zh) N-雜環衍生物作為氧化氮合酶抑制劑使用
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
WO2004018478A3 (fr) Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
WO2006005609A3 (fr) Derives d'oxindole substitues, et medicaments les renfermant
WO2004039753A3 (fr) Composes a base de phenyle
WO2003095455A3 (fr) Composes therapeutiques
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
IL164974A0 (en) Novel compounds and their use
WO2002048148A3 (fr) Composes therapeutiques
WO2005040171A8 (fr) Derives de pyrazolo-pyrimidine et d'imidazo-pyrimidine
WO2004096823A3 (fr) Nouveaux derives de ketolides
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2005075471A3 (fr) Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
WO2001010860A3 (fr) Derives de quinazolinone et d'azaquinazolinone
WO2005049604A3 (fr) Ethers aromatiques antithrombotiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 170348

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004717660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2517893

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006505701

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006217358

Country of ref document: US

Ref document number: 10548473

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004222540

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004222540

Country of ref document: AU

Date of ref document: 20040305

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004222540

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004717660

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408240

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10548473

Country of ref document: US